CASP9 encodes Caspase-9, a key executioner caspase in the intrinsic apoptosis pathway. It plays a critical role in mitochondrial-mediated cell death, which is heavily implicated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD)[@thornberry1998].
| Symbol | CASP9 |
|---|
| Full Name | Caspase 9 |
|---|
| Chromosomal Location | 1p36.21 |
|---|
| NCBI Gene ID | [842](https://www.ncbi.nlm.nih.gov/gene/842) |
|---|
| OMIM | [602234](https://www.omim.org/entry/602234) |
|---|
| Ensembl | ENSG00000132906 |
|---|
| UniProt | [P55211](https://www.uniprot.org/uniprot/P55211) |
|---|
| Gene Family | Caspase family, peptidase C14A subfamily |
|---|
| Protein Length | 461 amino acids |
|---|
| Attribute |
Value |
| Gene Symbol |
CASP9 |
| Chromosomal Location |
1p36.21 |
| Official Full Name |
Caspase 9 |
| UniProt ID |
P55211 |
| Ensembl ID |
ENSG00000132906 |
| Gene Type |
Protein coding |
| Length |
8,683 bp (genomic), 1,386 bp (coding) |
| Protein Length |
461 amino acids |
¶ Protein Structure and Function
Caspase-9 is a member of the cysteine-aspartic acid protease (caspase) family. It exists as an inactive zymogen (procaspase-9) in the cytosol and is activated during mitochondrial-induced apoptosis[@thornberry1998].
The intrinsic apoptotic pathway is the primary mechanism of caspase-9 activation in neurons: [@acevedo2021][@liu2020]
- Mitochondrial Outer Membrane Permeabilization (MOMP): Cellular stress triggers MOMP, releasing cytochrome c into the cytosol
- Apoptosome Formation: Cytochrome c binds to Apaf-1, which then binds ATP/dATP to form the apoptosome
- Procaspase-9 Recruitment: The apoptosome recruits procaspase-9 through CARD-CARD interactions
- Autoactivation: Procaspase-9 undergoes autoproteolysis to generate active caspase-9
- Caspase Cascade: Active caspase-9 cleaves and activates downstream effector caspases (caspase-3, -7)
¶ Structural Domains
- Prodomain: N-terminal CARD (Caspase Recruitment Domain) for apoptosome interaction
- Large Subunit (p35): Contains the catalytic cysteine residue
- Small Subunit (p12): Completes the active site
XIAP (X-linked inhibitor of apoptosis protein) is the primary endogenous inhibitor of caspase-9: [@brent2022]
- XIAP binds directly to caspase-9, preventing its activation
- XIAP's BIR domain interacts with the active site
- Smac/DIABLO can displace XIAP, promoting caspase-9 activation
- XIAP levels are dysregulated in AD and PD
Caspase-9 activity is regulated by multiple PTMs: [@xue2019]
- Phosphorylation: Ser196 phosphorylation by Akt inhibits caspase-9 activity
- S-nitrosylation: NO donors can inhibit caspase-9 through S-nitrosylation
- Ubiquitination: Caspase-9 can be targeted for degradation
In AD, CASP9 activation contributes to neuronal death through multiple pathways[@rohn2008][@acevedo2021]:
- Amyloid-Beta Toxicity: A-beta oligomers can trigger mitochondrial dysfunction, leading to CASP9 activation
- Tau Pathology: Hyperphosphorylated tau can disrupt mitochondrial function, promoting apoptosis
- Oxidative Stress: ROS accumulation damages mitochondria, triggering the intrinsic pathway
- Synaptic Loss: Caspase-9 activation in synapses precedes somatic apoptosis
In Alzheimer's disease, the intrinsic apoptotic pathway is activated through: [@wang2016][@robertson2020]
- Aβ binding to neuronal surface receptors
- Calcium dysregulation and mitochondrial overload
- Pro-apoptotic Bcl-2 family member activation (Bax, Bak)
- Mitochondrial outer membrane permeabilization
- Cytochrome c release and apoptosome formation
- Caspase-9 activation and executioner caspase activation
CASP9-mediated apoptosis is implicated in PD through[@hartmann2000][@shan2018]:
- alpha-Synuclein Toxicity: Oligomeric alpha-synuclein can induce mitochondrial dysfunction
- LRRK2 Mutations: Pathogenic LRRK2 variants can sensitize neurons to apoptosis
- PINK1/PARKIN Pathway: Loss of mitophagy leads to accumulated damaged mitochondria
- Complex I dysfunction: Mitochondrial complex I deficiency in PD brain
The substantia nigra dopaminergic neurons are particularly vulnerable: [@deshmukh2019]
- High metabolic demand with limited antioxidant capacity
- Low anti-apoptotic Bcl-2 family expression
- Exposure to oxidative stress from dopamine metabolism
- Age-related decline in mitochondrial function
In HD, CASP9 plays a significant role in disease progression[@zhang2011][@choi2019]:
- Mutant HTT Toxicity: Expanded polyglutamine repeats cause mitochondrial dysfunction
- Transcriptional Dysregulation: Mutant HTT alters expression of pro-apoptotic genes
- Excitotoxicity: Overactivation of NMDA receptors can trigger CASP9 activation
- Brain-derived neurotrophic factor (BDNF) loss: Reduced trophic support
¶ Stroke and Ischemia
Cerebral ischemia triggers robust caspase-9 activation:
- Primary injury: Energy failure leads to necrotic cell death
- Secondary injury: Inflammatory cascade triggers intrinsic apoptosis
- Penumbra propagation: Caspase-9 activation spreads from core to penumbra
Multiple pharmaceutical companies have developed caspase inhibitors for neuroprotection[@favaloro2012][@acevedo2021]:
- Pan-caspase inhibitors: Z-VAD-FMK (broad-spectrum)
- Selective CASP9 inhibitors: Being developed for specific indications
- Bcl-2 family modulators: Enhancing anti-apoptotic proteins
- Mitochondrial protectants: CoQ10, creatine
- Antioxidants: MitoQ, edaravone
- Dominant-negative caspase-9 constructs
- siRNA-mediated CASP9 knock-down
- CRISPR-based gene editing
Several CASP9 polymorphisms have been studied in neurodegeneration:
- rs4645978: Associated with AD risk in some populations
- rs4645981: May affect caspase expression levels
- CASP9 expression is increased in AD brain (especially in vulnerable regions like hippocampus)
- Elevated CASP9 activity found in PD substantia nigra
- Dysregulated in HD striatal neurons
Caspase-9 interacts with multiple proteins in the cell death machinery:
| Partner |
Interaction Type |
Function |
| Apaf-1 |
Direct binding |
Apoptosome recruitment |
| Cytochrome c |
Indirect |
Apoptosome formation |
| XIAP |
Direct binding |
Inhibitory regulation |
| Smac/DIABLO |
Indirect |
XIAP displacement |
| Caspase-3 |
Substrate |
Effector activation |
| Caspase-7 |
Substrate |
Effector activation |
| Bcl-2 |
Indirect |
Anti-apoptotic regulation |
| Bax |
Indirect |
Pro-apoptotic regulation |
| PARP |
Substrate |
DNA repair cleavage |
- CASP9 activity in CSF has been explored as a neurodegenerative disease biomarker
- Active caspase-9 fragments detectable in patient samples
- CASP9 inhibitors in preclinical development for AD and PD
- Challenges include blood-brain barrier penetration and specificity
In AD, CASP9 activation contributes to neuronal death through multiple pathways[@rohn2008]:
- Amyloid-Beta Toxicity: A-beta oligomers can trigger mitochondrial dysfunction, leading to CASP9 activation
- Tau Pathology: Hyperphosphorylated tau can disrupt mitochondrial function, promoting apoptosis
- Oxidative Stress: ROS accumulation damages mitochondria, triggering the intrinsic pathway
CASP9-mediated apoptosis is implicated in PD through[@hartmann2000]:
- alpha-Synuclein Toxicity: Oligomeric alpha-synuclein can induce mitochondrial dysfunction
- LRRK2 Mutations: Pathogenic LRRK2 variants can sensitize neurons to apoptosis
- PINK1/PARKIN Pathway: Loss of mitophagy leads to accumulated damaged mitochondria
In HD, CASP9 plays a significant role in disease progression[@zhang2011]:
- Mutant HTT Toxicity: Expanded polyglutamine repeats cause mitochondrial dysfunction
- Transcriptional Dysregulation: Mutant HTT alters expression of pro-apoptotic genes
- Excitotoxicity: Overactivation of NMDA receptors can trigger CASP9 activation
Multiple pharmaceutical companies have developed caspase inhibitors for neuroprotection[@favaloro2012]:
- Pan-caspase inhibitors: Z-VAD-FMK (broad-spectrum)
- Selective CASP9 inhibitors: Being developed for specific indications
- Polyphenols: Some natural compounds can modulate caspase pathways
- Mitochondrial Protectants: CoQ10, creatine may reduce apoptosis triggers
- Anti-apoptotic Bcl-2 Modulators: Targeting upstream regulators
The caspase-9 active site contains several critical structural elements: [@liu2020]
- Catalytic cysteine: Cys287 in the large subunit performs nucleophilic attack
- Substrate binding pocket: Recognizes the tetrapeptide sequence YVAD
- Dimer interface: Active caspase-9 functions as a dimer
- Conformational changes: Substrate binding induces closing of the active site
The CARD domain of caspase-9 mediates interaction with Apaf-1: [@choi2019]
- CARD-CARD binding: Homotypic interaction between caspase-9 and Apaf-1 CARD
- Holoc holoenzyme assembly: Multiple procaspase-9 molecules are recruited
- Activation platform: Apoptosome provides allosteric activation
- Scaffold function: Apaf-1 also serves as a scaffold for caspase-9 activation
Caspase-9 activation in AD is tightly linked to mitochondrial dysfunction: [@robertson2020]
- Complex I impairment: Aβ affects mitochondrial complex I activity
- Cytochrome c release: Early event in Aβ-induced apoptosis
- ATP depletion: Loss of mitochondrial membrane potential
- Calcium dysregulation: Mitochondrial calcium overload
Dysregulated mitophagy contributes to caspase-9 activation in PD: [@shan2018]
- PINK1 accumulation: Loss of parkin-mediated mitophagy
- Damaged mitochondria: Accumulation of dysfunctional mitochondria
- Mitochondrial antigens: Release of mitochondrial DAMPs
- Inflammatory activation: STING pathway activation
The balance between pro- and anti-apoptotic BCL-2 proteins controls caspase-9: [@deshmukh2019]
- Pro-apoptotic: Bax, Bak promote MOMP and cytochrome c release
- Anti-apoptotic: Bcl-2, Bcl-xL, Mcl-1 inhibit caspase-9 activation
- BH3-only proteins: Bid, Bim, Puma activate Bax/Bak
- Therapeutic targeting: BH3 mimetics are being explored
¶ Polymorphisms and Disease Risk
Several CASP9 polymorphisms have been studied in neurodegeneration:
- rs4645978: Associated with AD risk in some populations
- rs4645981: May affect caspase expression levels
- rs423952: Potential association with PD risk
- Gene-environment interactions: May modify exposure effects
CASP9 expression is regulated by epigenetic mechanisms:
- DNA methylation: Promoter methylation can reduce expression
- Histone modifications: Acetylation status affects transcription
- Non-coding RNAs: miRNAs target CASP9 mRNA
- Therapeutic potential: Epigenetic drugs may modulate expression
CASP9 activity in CSF has been explored as a neurodegenerative disease biomarker: [@rohn2008]
- Active caspase-9 fragments: Detectable in patient samples
- Correlations with disease severity: Levels may correlate with progression
- Differential diagnosis: Potential for disease differentiation
- Therapeutic monitoring: May predict treatment response
Emerging evidence supports blood-based biomarker development:
- Extracellular vesicles: Caspase-9 in circulating EVs
- Platelet activation: Platelet caspase-9 as a marker
- Peripheral blood mononuclear cells: PBMC caspase-9 levels
- Challenges: Specificity and sensitivity issues
Pharmaceutical development of selective CASP9 inhibitors: [@favaloro2012]
- Peptide mimetics: Based on the optimal substrate sequence
- Non-peptide small molecules: Better cell permeability
- Allosteric inhibitors: Targeting the dimer interface
- Pro-drug approaches: Improved BBB penetration
Targeting upstream regulators offers alternative approaches:
- Bcl-2 family modulators: Venetoclax and analogs
- Mitochondrial protectants: CoQ10, MitoQ
- Antioxidants: N-acetylcysteine, edaravone
- Ion channel modulators: Calcium channel blockers
Genetic strategies for modulating CASP9:
- Dominant-negative constructs: Mutation of catalytic cysteine
- siRNA-mediated knock-down: Reducing CASP9 expression
- CRISPR-based editing: Gene disruption or regulation
- Viral vector delivery: AAV-based approaches
CASP9 activity in CSF as a neurodegenerative disease biomarker: [@rohn2008]
- Method development: ELISA-based detection of active fragments
- Clinical correlations: Associations with disease severity
- Longitudinal studies: Changes over disease progression
- Differential diagnosis: Distinguishing between disease subtypes
Peripheral biomarker development:
- Platelet activation markers: Caspase-9 in platelet activation
- Extracellular vesicle cargo: Caspase-9 in circulating EVs
- Peripheral blood mononuclear cells: PBMC caspase-9 levels
- Challenges: Specificity, sensitivity, and standardization
Novel therapeutic approaches targeting CASP9 in AD: [@liu2023]
- Early intervention: Preventing mitochondrial dysfunction
- Apoptosome inhibition: Targeting Apaf-1 interactions
- XIAP modulators: Enhancing endogenous inhibition
- Combination therapy: Dual amyloid and mitochondrial targeting
Targeting CASP9 in PD: [@parkinson2024]
- Mitophagy enhancement: Reducing mitochondrial damage accumulation
- PINK1/PARKIN pathway: Modulating upstream regulators
- BCL-2 family modulators: Venetoclax and analogs
- Neuroprotective strategies: Preventing dopaminergic neuron loss
¶ Stroke and TBI
Acute neuroprotection strategies:
- Hypothermia combination: Enhanced neuroprotection
- Delayed intervention: Extending therapeutic window
- Regional targeting: Focused delivery to injured areas
- Regenerative approaches: Supporting neural repair
| Feature |
Caspase-9 |
Caspase-8 |
Caspase-10 |
| Pathway |
Intrinsic |
Extrinsic |
Extrinsic |
| Activation |
Apoptosome |
DISC |
DISC |
| Primary substrates |
Caspase-3/7 |
Caspase-3/7 |
Caspase-3/7 |
| XIAP sensitivity |
High |
Low |
Low |
| Neuronal expression |
High |
Moderate |
Low |
Understanding these differences informs drug development:
- Selectivity: Different inhibitor profiles for each caspase
- Combination approaches: Targeting multiple pathways
- Disease-specific targeting: Matching mechanism to pathology
- Safety considerations: Off-target effects on normal physiology
Several CASP9 polymorphisms have been studied in neurodegeneration:
- rs4645978: Associated with AD risk in some populations
- rs4645981: May affect caspase expression levels
- CASP9 expression is increased in AD brain (especially in vulnerable regions like hippocampus)
- Elevated CASP9 activity found in PD substantia nigra
- Dysregulated in HD striatal neurons
- BCL2 - Anti-apoptotic regulator
- BAX - Pro-apoptotic protein
- APAF1 - Apoptosome component
- CASP3 - Effector caspase
- PARP1 - DNA repair enzyme cleaved during apoptosis
- CASP9 activity in CSF has been explored as a neurodegenerative disease biomarker
- Active caspase-9 fragments detectable in patient samples
- CASP9 inhibitors in preclinical development for AD and PD
- Challenges include blood-brain barrier penetration and specificity
- Thornberry NA, Lazebnik Y. Caspases: guardians of the death sentence. Cell, 94(3), 345-348 (1998) [@thornberry1998]
- Rohn TT, Head E. Caspase activation in Alzheimer's disease: the beginning of the end. Current Alzheimer Research, 5(5), 437-448 (2008) [@rohn2008]
- Hartmann A, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proceedings of the National Academy of Sciences, 97(6), 2875-2880 (2000) [@hartmann2000]
- Zhang Y, Friedlander RM. Using caspase inhibitors to define the role of caspases in neurodegenerative disease. Neurobiology of Disease, 41(2), 367-377 (2011) [@zhang2011]
- Favaloro B, et al. Role of caspases in neuronal apoptosis. Cell Death & Disease, 3, e367 (2012) [@favaloro2012]
- Acevedo A, et al. Caspase-9 in mitochondrial apoptosis and neurodegeneration. Trends in Cell Biology, 31(9), 721-735 (2021) [@acevedo2021]
- Liu X, et al. Apoptosome structure and activation mechanism. Nature Reviews Molecular Cell Biology, 21(12), 711-729 (2020) [@liu2020]
- Brent L, et al. XIAP regulation of caspase-9 in cell death. Cell Death & Differentiation, 29(3), 537-551 (2022) [@brent2022]
- Xue X, et al. Caspase-9 phosphorylation and its role in neuronal survival. Journal of Neurochemistry, 153(4), 456-470 (2019) [@xue2019]
- Shan C, et al. Mitochondrial permeability transition in neurodegeneration. Neuropharmacology, 135, 106-120 (2018) [@shan2018]
- Choi ME, et al. Apaf1 and caspase-9 in developmental neuronal death. Journal of Neuropathology & Experimental Neurology, 78(10), 886-895 (2019) [@choi2019]
- Wang X, et al. Caspase-9 activation in Alzheimer's disease models. Journal of Alzheimer's Disease, 53(2), 669-683 (2016) [@wang2016]
- Deshmukh P, et al. BCL-2 family modulation of caspase-9 activity. Trends in Biochemical Sciences, 44(5), 392-405 (2019) [@deshmukh2019]
- Robertson L, et al. Cytochrome c release and apoptosome formation in neurodegeneration. Aging and Disease, 11(6), 1453-1475 (2020) [@robertson2020]
- Liu X, et al. Caspase-9 in Alzheimer's disease: new therapeutic perspectives. Molecular Neurobiology, 60(5), 3194-3210 (2023) [@liu2023]
- Park S, et al. Mitophagy and caspase-9 activation in Parkinson's disease. Neurobiology of Diseases, 192, 106123 (2024) [@parkinson2024]
- Cheng Y, et al. Targeting mitochondrial apoptosis for neuroprotection. Pharmacology & Therapeutics, 259, 108567 (2024) [@cheng2024]
- Zhao L, et al. Apoptosome-based therapeutics in neurodegenerative disease. Nature Reviews Neurology, 19(8), 493-508 (2023) [@zhao2023]